Patents by Inventor Athisayamani Jeyaraj Duraiswamy

Athisayamani Jeyaraj Duraiswamy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11555037
    Abstract: The invention relates to the use of compounds of general structure (I) in modulation of the Wnt pathway wherein R1, R2, R3, R4 and R5 are each, independently, H or an alkyl group; D is selected from the group consisting of H, halogen, alkyl, cycloalkyl, aryl, and dialkylamino, each (other than H and halogen) being optionally substituted; Ar is an aryl or heteroaryl group, optionally substituted; Cy is an aryl, heteroaryl or a saturated ring containing at least one heteroatom, each being optionally substituted; and n is an integer from 1 to 3.
    Type: Grant
    Filed: November 20, 2020
    Date of Patent: January 17, 2023
    Assignee: Agency for Science, Technology and Research
    Inventors: Soo Yei Ho, Stephanie Eliane Blanchard, Athisayamani Jeyaraj Duraiswamy, Jenefer Alam, Vikrant Arun Adsool
  • Publication number: 20220281885
    Abstract: Described herein are compounds that are TYK2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of TYK2 activity.
    Type: Application
    Filed: May 5, 2022
    Publication date: September 8, 2022
    Inventors: Anjali PANDEY, Gregory DIETSCH, Bhaskar CHAUDHURI, Seetharaman MANOJVEER, Mahesh THAKKAR, Athisayamani Jeyaraj DURAISWAMY, Sukesh KALVA
  • Patent number: 11434245
    Abstract: The present invention relates to compounds of formula (I), combinations and uses thereof for disease therapy, or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof wherein.
    Type: Grant
    Filed: October 29, 2020
    Date of Patent: September 6, 2022
    Assignee: Agency for Science, Technology and Research
    Inventors: Jenefer Alam, Soo Yei Ho, Wei Ling Wang, Athisayamani Jeyaraj Duraiswamy
  • Patent number: 11426412
    Abstract: Heterocyclic compounds of Formula (I), (II), and (III) are described herein along with their polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts, and metabolites thereof. The compounds described herein, their polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts, and metabolites thereof are PAD4 inhibitors and may be useful in the treatment of various disorders, for example rheumatoid arthritis, vasculitis, systemic lupus erythematosis, cutaneous lupus erythematosis, ulcerative colitis, cancer, cystic fibrosis, asthma, multiple sclerosis and psoriasis.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: August 30, 2022
    Assignee: JUBILANT EPIPAD LLC
    Inventors: Gurulingappa Hallur, Athisayamani Jeyaraj Duraiswamy, Buchi Reddy Purra, N.V.S.K. Rao, Sridharan Rajagopal, Rajendra Kristam
  • Publication number: 20220227765
    Abstract: This present disclosure relates to compounds with ferroptosis inducing activity, a method of treating a subject with cancer with the compounds, and combination treatments with a second therapeutic agent.
    Type: Application
    Filed: August 26, 2020
    Publication date: July 21, 2022
    Inventors: Anjali Pandey, Chun Jiang, Ruihong Chen, Biswajit Kalita, Athisayamani Jeyaraj Duraiswamy
  • Publication number: 20220098214
    Abstract: The present invention provides compounds and methods for treating MKP5 modulated disease. In certain embodiments, the MKP5 modulated disease is a fibrotic disease.
    Type: Application
    Filed: January 30, 2020
    Publication date: March 31, 2022
    Inventors: Anton BENNETT, Gurulingappa HALLUR, Chandregowda VENKATESHAPPA, Athisayamani Jeyaraj DURAISWAMY, Rama Kishore V.P. PUTTA
  • Publication number: 20220002280
    Abstract: This present disclosure relates to compounds with ferroptosis inducing activity, a method of treating a subject with cancer with the compounds, and combination treatments with a second therapeutic agent.
    Type: Application
    Filed: April 5, 2021
    Publication date: January 6, 2022
    Inventors: Chun Jiang, Anjali Pandey, Ruihong Chen, Biswajit Kalita, Athisayamani Jeyaraj Duraiswamy
  • Patent number: 11098040
    Abstract: This present disclosure relates to compounds with ferroptosis inducing activity, a method of treating a subject with cancer with the compounds, and combination treatments with a second therapeutic agent.
    Type: Grant
    Filed: February 27, 2019
    Date of Patent: August 24, 2021
    Assignee: Ferro Therapeutics, Inc.
    Inventors: Chun Jiang, Ruihong Chen, Anjali Pandey, Biswajit Kalita, Athisayamani Jeyaraj Duraiswamy
  • Patent number: 11040978
    Abstract: The present invention relates to compounds of Formula (Ib-I) that act as inhibitors of the MAP kinase interacting kinases MNK2a, MNK2b, MNK1a, and MNK1b. The present invention further relates to pharmaceutical compositions comprising these compounds, and to the use of the compounds for the preparation of a medicament for the prophylaxis and treatment of diseases (e.g., proliferative diseases (e.g., cancer), inflammatory diseases, Alzheimer's disease), as well as methods of treating these diseases.
    Type: Grant
    Filed: June 5, 2019
    Date of Patent: June 22, 2021
    Assignee: Agency for Science, Technology and Research
    Inventors: Kassoum Nacro, Athisayamani Jeyaraj Duraiswamy, Lohitha Rao Chennamaneni
  • Patent number: 11040964
    Abstract: This present disclosure relates to compounds with ferroptosis inducing activity, a method of treating a subject with cancer with the compounds, and combination treatments with a second therapeutic agent.
    Type: Grant
    Filed: February 27, 2020
    Date of Patent: June 22, 2021
    Assignee: Ferro Therapeutics, Inc.
    Inventors: Chun Jiang, Anjali Pandey, Ruihong Chen, Biswajit Kalita, Athisayamani Jeyaraj Duraiswamy
  • Publication number: 20210179580
    Abstract: The compounds of Formula Ib, Formula Ia, and Formula I are described herein along with their polymorphs, stereoisomers, tautomers, prodrugs, solvates, and pharmaceutically acceptable salts thereof. The process of preparation of the compounds of Formula Ib, Formula Ia, and Formula I is also described. The compounds described herein, their polymorphs, stereoisomers, tautomers, prodrugs, solvates, and pharmaceutically acceptable salts thereof are 2-(benzyloxy)pyrimidine derivatives that are inhibitors of PD-1/PD-L1 activation.
    Type: Application
    Filed: November 6, 2018
    Publication date: June 17, 2021
    Inventors: Chandregowda VENKATESHAPPA, Athisayamani Jeyaraj DURAISWAMY, Rama Kishore V P PUTTA, Sridharan RAJAGOPAL
  • Publication number: 20210155623
    Abstract: The invention relates to the use of compounds of general structure (I) in modulation of the Wnt pathway wherein R1, R2, R3, R4 and R5 are each, independently, H or an alkyl group; D is selected from the group consisting of H, halogen, alkyl, cycloalkyl, aryl, and dialkylamino, each (other than H and halogen) being optionally substituted; Ar is an aryl or heteroaryl group, optionally substituted; Cy is an aryl, heteroaryl or a saturated ring containing at least one heteroatom, each being optionally substituted; and n is an integer from 1 to 3.
    Type: Application
    Filed: November 20, 2020
    Publication date: May 27, 2021
    Applicant: Agency for Science, Technology and Research
    Inventors: Soo Yei Ho, Stephanie Eliane BLANCHARD, Athisayamani Jeyaraj DURAISWAMY, Jenefer ALAM, Vikrant Arun ADSOOL
  • Publication number: 20210047336
    Abstract: The present invention relates to compounds of formula (I), combinations and uses thereof for disease therapy, or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof wherein R1 represents H; optionally substituted alkyl (wherein optional substituents include one or more substituents each independently selected from C1-6alkoxy, NH2, —NHC1-3alkyl and —N(C1-3alkyl)2); —C(O)Oalkyl; haloalkyl; haloalkoxy; or -alkylaryl; each R2 independently represents H; optionally substituted alkyl (wherein optional substituents include one or more substituents each independently selected from C1-6alkoxy, NH2, —NHC1-3alkyl and —N(C1-3alkyl)2); -alkylaryl; optionally substituted carbocyclyl (wherein optional substituents include one or more substituents each independently selected from C1-6alkyl, C1-6alkoxy, C1-6haloalkyl, C1-6haloalkoxy and halo); optionally substituted heterocyclyl (wherein optional substituents include one or more substituents each independentl
    Type: Application
    Filed: October 29, 2020
    Publication date: February 18, 2021
    Applicant: Agency for Science, Technology and Research
    Inventors: Jenefer Alam, Soo Yei Ho, Wei Ling Wang, Athisayamani Jeyaraj Duraiswamy
  • Patent number: 10870653
    Abstract: The present invention relates to compounds of formula (I), combinations and uses thereof for disease therapy, or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof wherein each of R1, R2, R3, R4, R5, W, X, Y, Z, and n is as defined herein.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: December 22, 2020
    Assignee: Agency for Science, Technology and Research
    Inventors: Jenefer Alam, Soo Yei Ho, Wei Ling Wang, Athisayamani Jeyaraj Duraiswamy
  • Patent number: 10844063
    Abstract: The invention relates to the use of compounds of general structure (I) in modulation of the Wnt pathway [Formula should be inserted here] wherein R1, R2, R3, R4 and R5 are each, independently, H or an alkyl group; D is selected from the group consisting of H, halogen, alkyl, cycloalkyl, aryl, and dialkylamino, each (other than H and halogen) being optionally substituted; Ar is an aryl or heteroaryl group, optionally substituted; Cy is an aryl, heteroaryl or a saturated ring containing at least one heteroatom, each being optionally substituted; and n is an integer from 1 to 3.
    Type: Grant
    Filed: December 16, 2019
    Date of Patent: November 24, 2020
    Assignee: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
    Inventors: Soo Yei Ho, Stephanie Eliane Blanchard, Athisayamani Jeyaraj Duraiswamy, Jenefer Alam, Vikrant Arun Adsool
  • Publication number: 20200299283
    Abstract: This present disclosure relates to compounds with ferroptosis inducing activity, a method of treating a subject with cancer with the compounds, and combination treatments with a second therapeutic agent.
    Type: Application
    Filed: February 27, 2020
    Publication date: September 24, 2020
    Inventors: Chun Jiang, Anjali Pandey, Ruihong Chen, Biswajit Kalita, Athisayamani Jeyaraj Duraiswamy
  • Publication number: 20200276206
    Abstract: Heterocyclic compounds of Formula (I), (II), and (III) are described herein along with their polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts, and metabolites thereof. The compounds described herein, their polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts, and metabolites thereof are PAD4 inhibitors and may be useful in the treatment of various disorders, for example rheumatoid arthritis, vasculitis, systemic lupus erythematosis, cutaneous lupus erythematosis, ulcerative colitis, cancer, cystic fibrosis, asthma, multiple sclerosis and psoriasis.
    Type: Application
    Filed: September 20, 2018
    Publication date: September 3, 2020
    Inventors: Gurulingappa HALLUR, Athisayamani Jeyaraj DURAISWAMY, Buchi Reddy PURRA, N.V.S.K. RAO, Sridharan RAJAGOPAL
  • Publication number: 20200237771
    Abstract: Heterocyclic compounds of Formula (I), (II), and (III) are described herein along with their polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts, and metabolites thereof. The compounds described herein, their polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts, and metabolites thereof are PAD4 inhibitors and may be useful in the treatment of various disorders, for example rheumatoid arthritis, vasculitis, systemic lupus erythematosis, cutaneous lupus erythematosis, ulcerative colitis, cancer, cystic fibrosis, asthma, multiple sclerosis and psoriasis.
    Type: Application
    Filed: October 16, 2018
    Publication date: July 30, 2020
    Inventors: Gurulingappa HALLUR, Athisayamani Jeyaraj DURAISWAMY, Buchi Reddy PURRA, N.V.S.K. RAO, Sridharan RAJAGOPAL, Rajendra KRISTAM
  • Publication number: 20200190086
    Abstract: The invention relates to the use of compounds of general structure (I) in modulation of the Wnt pathway [Formula should be inserted here] wherein R1, R2, R3, R4 and R5 are each, independently, H or an alkyl group; D is selected from the group consisting of H, halogen, alkyl, cycloalkyl, aryl, and dialkylamino, each (other than H and halogen) being optionally substituted; Ar is an aryl or heteroaryl group, optionally substituted; Cy is an aryl, heteroaryl or a saturated ring containing at least one heteroatom, each being optionally substituted; and n is an integer from 1 to 3.
    Type: Application
    Filed: December 16, 2019
    Publication date: June 18, 2020
    Applicant: Agency for Science, Technology and Research
    Inventors: Soo Yei HO, Stephanie Eliane BLANCHARD, Athisayamani Jeyaraj DURAISWAMY, Jenefer ALAM, Vikrant Arun ADSOOL
  • Patent number: 10526335
    Abstract: The invention relates to the use of compounds of general structure (I) in modulation of the Wnt pathway [Formula should be inserted here] wherein R1, R2, R3, R4 and R5 are each, independently, H or an alkyl group; D is selected from the group consisting of H, halogen, alkyl, cycloalkyl, aryl, and dialkylamino, each (other than H and halogen) being optionally substituted; Ar is an aryl or heteroaryl group, optionally substituted; Cy is an aryl, heteroaryl or a saturated ring containing at least one heteroatom, each being optionally substituted; and n is an integer from 1 to 3.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: January 7, 2020
    Assignee: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
    Inventors: Soo Yei Ho, Stephanie Eliane Blanchard, Athisayamani Jeyaraj Duraiswamy, Jenefer Alam, Vikrant Arun Adsool